- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03213366
Social Media Based Peer-Led Intervention for HIV Prevention
Empowering With PrEP Cluster-Randomized Controlled Trial: A Social Media Based Peer-Led Intervention for HIV Prevention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study examines a social media based peer-led and delivered intervention focused on increasing PrEP adoption in young men of color who have sex with men (YMCSM). While prior efficacy trials have included YMCSM 18-29, we will focus on PrEP in YMCSM outside clinical trial settings. Rather than an alternative medium for implementation of existing interventions designed for in-person contact, social media may be a true 'game changer' to engage hard to reach individuals. While many online behavioral interventions exist, including some that use social media, this will be one of the few studies to use and test social media to facilitate uptake of a biomedical intervention. E-PrEP will connect the target population (YMCSM) to a new prevention tool (PrEP) through rapid linkage to medical care, accelerating diffusion of PrEP. Given the paucity of data regarding social media-based interventions to change health-related behavior, E-PrEP may have a marked impact on future bio-behavioral interventions, especially those that include diffusion of innovation. Social media offers the power of scale and efficiency for large potential impact, even with relatively low-intensity interventions. Similarly, PrEP, if widely adopted in high-risk populations and offered with behavioral interventions, could markedly decrease HIV infection rates. Social media-based, peer-led approaches like E-PrEP could be used to enhance efforts by community-based and other organizations that employ internet-assisted or peer-outreach strategies to improve health.
Primary Aim: To test the feasibility and preliminary efficacy of E-PrEP for increasing PrEP adoption in a cluster-randomized controlled trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10467
- Albert Einstein College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Transgender individual; Ages 18-29; Have had unprotected anal sex with a male partner in the prior 12 months; Fluent in English or Spanish; Are HIV-negative or unknown status (self-report); Identify as Black and/or Latino
Exclusion Criteria:
- YMCSM who do not consent/assent to study; not currently using at least one of 2 social media sites that will be used for the E-PrEP intervention (not using Facebook, or Instagram), and do not live in New York City.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: E-PrEP- Peer-Led Intervention about PrEP
8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm.
Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms.
PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues.
All contents will be formatted to be both mobile device accessible.
|
Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs.
The contents were developed or adapted by study staff and peer leaders.
Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics.
Posts will also include information about linkage-to-care, and insurance access.
New contents will be posted almost daily.
|
ACTIVE_COMPARATOR: BxNow - General Health Campaign
BxNow is an attention-matched control.
Eight of the 16 PLs will be randomly assigned to the BxNow arm.
The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm.
Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups.
General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
|
BxNow will focus on general health topics unrelated to HIV or sexual health (i.e.
fitness, nutrition, smoking), as chosen by PLs.
Contents will be developed or adapted by PLs and posted almost daily.
Posts will also include information about linkage-to-care and insurance access.
At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Intending to Start Using PrEP Over Time
Time Frame: baseline, 6 weeks, and 12 weeks
|
This primary outcome is intention to use PrEP in the next month measured at baseline, 6 weeks, and 12 weeks. This was assessed with a yes/no question (dichotomous variable). However, this variable does not include anyone who reported PrEP use at either 6 or 12 weeks. This outcome will inform sample size calculations for a subsequent fully powered trial. |
baseline, 6 weeks, and 12 weeks
|
Number of Participants Using PrEP Over Time
Time Frame: at baseline, 6 weeks, and 12 weeks
|
This outcome is the number of participants who self-report using PrEP at baseline, 6 weeks, or 12 weeks.
This was measure by a yes/no question asking if the participant currently uses PrEP (dichotomous variable).
|
at baseline, 6 weeks, and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PrEP Knowledge
Time Frame: at baseline, 6 weeks, and 12 weeks
|
Self-reported PrEP related knowledge. Participants were asked two questions about PrEP knowledge. For each question, they got one point if the answer was correct. Scale range from 0-2. The score were added and the average of the sum was reported. The higher the score, the higher the knowledge of PrEP. |
at baseline, 6 weeks, and 12 weeks
|
PrEP Awareness
Time Frame: baseline, 6 weeks, 12 weeks
|
Awareness about PrEP. PrEP awareness was measured with one question, scored 1 to 5. The mean for each arm was calculated at each time point. The higher the score, the higher the level of awareness about PrEP. |
baseline, 6 weeks, 12 weeks
|
PrEP Stigma
Time Frame: baseline, 6 weeks, 12 weeks
|
Any stigma the participant might have about PrEP or those who use PrEP To measure PrEP Stigma we asked 3 questions, using a Likert scale (from 1-4; 1= Strongly Disagree, 4=Strongly Agree). The scores were summed for each participant. The scores range from 1-12, with higher scores indicating higher levels of PrEP Stigma. The higher the score, the higher the level of PrEP stigma. |
baseline, 6 weeks, 12 weeks
|
Communication About PrEP
Time Frame: baseline, 6 weeks, 12 weeks
|
Discussion of PrEP with friends, partners, or family. Communication about PrEP was measured with 2 questions, using a Likert scale ( from 1-5;1=Not at all, 5= Extremely). The scores of the 2 questions were summed for each participant. The scores range from 1-10, with higher the score indicating higher the level of communication about PrEP (i.e. higher scores indicates participants communicating more about PrEP). |
baseline, 6 weeks, 12 weeks
|
PrEP Barriers
Time Frame: baseline, 6 weeks, 12 weeks
|
Any Barriers to PrEP uptake. To measure barriers to PrEP uptake, 7 items were used. Each item was measured using a likert scale ( from 1-4; 1=Strongly Disagree, 4= Strongly Agree). The scores of each question were summed for each participant (scale scores ranged 1-28, with higher scores indicating higher levels of PrEP Barriers). The higher the score, the higher the number of PrEP Barriers. |
baseline, 6 weeks, 12 weeks
|
Self-efficacy About Using PrEP
Time Frame: at baseline, 6 weeks, and 12 weeks
|
Self-reported answer to questions about self-efficacy of using PrEP.
There were two questions to measure self-efficacy of PrEP using a Likert scale (ranging from 1-5; 1=Not at all, 5=Extremely).
The scores from both questions were summed for each participant.
The scale range from 1-10 with higher scores indicating higher the levels of PrEP self-efficacy.
|
at baseline, 6 weeks, and 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Self-reported HIV Testing
Time Frame: at baseline, 6 weeks, and 12 weeks
|
Self-reported HIV testing at baseline, 6 weeks, and 12 weeks.
|
at baseline, 6 weeks, and 12 weeks
|
Number of Participants With Self-reported Linkage-to-Care
Time Frame: at baseline, 6 weeks, and 12 weeks
|
Self-reported information about health care access (i.e.
going to a medical appointment).
|
at baseline, 6 weeks, and 12 weeks
|
Trust in the Peer by Participant
Time Frame: at baseline and 6 weeks
|
The scale measure the level of trust the Participant had on the Peer's online post. Trust in the Peer Leader was measured using 4 questions, each scored from 1-7 (1=Strongly Disagree, 7=Strongly Agree). The score for the 4 questions was summed for each participant. The score ranged from 1-28 with higher scores indicating a higher level of trust the participant had in their Peer Leader. |
at baseline and 6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Viraj Patel, MD, MPH, Montefiore Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 2016-7263
- 5K23MH102118-04 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Prevention
-
Prof Mags BeksinskaCompletedHIV Prevention | Pregnancy PreventionSouth Africa
-
Yale UniversityCompletedHIV Prevention | STI PreventionUnited States
-
Centers for Disease Control and PreventionUniversity of Minnesota; The Fenway Institute; AIDS Action Committee of Massachusetts and other collaboratorsCompletedHIV Prevention | STD PreventionUnited States
-
International Partnership for Microbicides, Inc.CompletedHIV PreventionSouth Africa, Uganda
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompleted
-
Fenway Community HealthCompleted
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUganda, South Africa, Zimbabwe
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompleted
-
Orion Biotechnology Polska Sp. z o.o.Scope International AGCompleted
Clinical Trials on E-PrEP- Peer-Led Intervention about PrEP
-
Boston UniversityThe Brooklyn Hospital Center; Justice Resource Institute; Puerto Rico Community... and other collaboratorsCompleted
-
University of MiamiCompleted
-
CrescentCareRecruiting
-
Indiana UniversityNational Institutes of Health (NIH); National Center for Advancing Translational... and other collaboratorsEnrolling by invitationStigma, Social | HIV Pre-exposure ProphylaxisKenya
-
Fenway Community HealthHarvard UniversityCompletedPre-Exposure ProphylaxisUnited States
-
Institut de Recherche pour le DeveloppementUniversity of Health Sciences, Phnom Penh, Cambodia; National Center for HIV...Completed
-
University of California, San FranciscoNational Institute of Nursing Research (NINR); San Francisco Department of...CompletedHIV/AIDSUnited States
-
University of WashingtonKenyatta National Hospital; Fogarty International Center of the National Institute...Active, not recruitingPrEP Uptake | HIV Antibody PositivityKenya
-
Fred Hutchinson Cancer CenterNational Institute of Mental Health (NIMH)RecruitingHIV PreventionKenya
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed